# TO VALVE OR NOT TO VALVE - THE DECISION MAKING PROCESS IN THE PAEDIATRIC TRACHEOSTOMY VENTILATED POPULATION

Jo Matthews, Advanced Paediatric Speech and Language Therapist (SLT) Audrey Martin, Advanced Paediatric Respiratory Physiotherapist (PT) Birmingham Women's and Children's NHS Trust

## **INTRODUCTION**

The One-Way Tracheostomy Valve (OWV) offers more than just speech benefits. A review by Zabih et al. (2017) highlights that most research focuses on OWV use and tolerance rather than broader multisystem impacts, emphasising the need for further studies to reduce morbidity and mortality in paediatric patients. Similarly, Lian et al. (2022) call for standardised OWV use in an adult cohort.

Despite existing guidelines, there is no comprehensive decision-making tool to address all aspects of OWV consideration for patients with tracheostomy and long-term ventilation (tr-LTV) within an individualised, holistic framework. This gap increases the risk of inconsistent OWV decision making and management, potentially compromising patient safety and care quality and equality, especially in teams lacking experienced practitioners.

The authors have developed a comprehensive OWV decision-making tool for use with the paediatric tr-LTV population with the aim of standardising the OWV decision making process. This tool enables practitioners to consider patient safety and risk within the context of prognosis, well-being and quality of life.

### **METHODS**

The authors developed a comprehensive OWV decisionmaking tool with three core components:

- 1. Key Clinical Considerations for OWV Use -Structured into a RAG (Red-Amber-Green) format:
- Red Significant caution/high risk
- **Amber** Caution/medium risk (requiring further evaluation)
- Green Proceed/low risk
- 2. Predicted OWV Benefits Individual to each child.
- 3. Predicted Long-Term Ventilation (LTV) and **Tracheostomy Pathway** –Based on the 'Bridge to Recovery' or 'Destination' framework outlined by Brookes (2019) and adapted by the authors for tracheostomy prognosis and management.

#### **Development Process**

The tool was designed using a multi-faceted approach:

- Retrospective analysis of previous clinical OWV assessments and outcomes.
- **Informal thematic analysis** of common practitioner queries around OWV consideration and use, as well as feedback from parents and patients.
- Multi-professional expertise, integrating perspectives from SLTs, RPs, and other healthcare professionals.
- Review of relevant literature and resources, including the Passy Muir website and cited references

#### **Pilot Testing & Implementation**

The tool was piloted with 10 tr-LTV patients, refined based on findings, and finalised to optimise its usability in clinical decision making. Effective implementation required joint assessment by SLT and RP, alongside multidisciplinary collaboration with healthcare professionals, patients, and families.

## **RESULTS**

Figure 1: Matthews & Martin OWV decision-making tool

Patient Information		1	Predicted OWV Benefits			
Patient Name	******	1	Benefit for Valve trial		Comment	
	******	+			Comment	-
atient Number		4	Upper airway Resensitisation	X	1	4
ge	13months		Upper airway Rehabilitation	Х		
Veight	9.2kg	4	Swallow Function	х		4
Current status	narrow upper airway, trache,	1	Cough effectiveness	х		
мн	Pierre Robin Sequence, cleft palate		Upper airway Secretion Management			
Seneral Status	well, awaiting gastrostomy and cleft		Lower airway Secretion			-
Circles Guitas	repair, awaiting discharge		Management	×		
		•	Restoring physiological PEEP/Time off ventilator	×		1
			Voice/vocalisation	x		
As disat Dathwess	Pathways Bridge to recovery	Destination	Tone and trunk stability Other	X		
Medical Pathway TV	x x	Destination	Other		<del> </del>	_
rache	х					
			inical Considerations			
Parameter	Comment	Red (significant caution/high risk)	Amber (caution/medium risk)	Green (proceed/lowrisk)	Supplemetary considerations	Additional comments
atient weight	9.2kg	Caution/ingir11skj	х		Potential lack of space	Low weight for age
Nin stat Disease sale	landa del constituto de la facilitata				around tube	
Clincial Diagnosis PMH	known risk, unable to mitigate		x x		Manometry	1
General status	stable			×		
urway						1
	Name				M	Cervical Auscultation
TB outcome	Narrow airways		x		Manometry	
Supraglottis			Х		Manometry	Cervical Auscultation
Blottis				x		1
ubglottis			х		Manometry	Cervical Auscultation
rache tube type	Bivona Flextend			x		1
ize (diameter)	3.5		×		No downsize	? upper airway leak
iize (length)	nead			X		
Cuffed/uncuffed	uncuffed			Ŷ		1
ancaranculled				<u>.</u>		+
lange	straight			X		
toma (large, well healed, wet)	red/sticky		х			Stoma health not optimised - ENT review
ther						
fentilation Self ventilating						
aturations						
kygen	X					
nvasively Ventilated				x		
'entilator model	astral			x		
fode	ST			x		
lingle/dual limb	single			x		
Dry circuit tolerance	dry all day			x		
PAP Ventilation Pressures (cmH20)	15			x		
PAP Ventilation Pressures (cmH20)	8			x		
aturations	95			×		
Oxygen (%)	21%			v		
ime off Ventilator	2 x 1.5hours			<u>.</u>		
ane on venticator	Z X 1.5IIOUIS					
Recent escalation	N/A					1
Recent de-escalation	N/A					1
table ventilation	yes			x		1
Vork of Breathing	yes, moderate		Х			Normal for patient
uscultation	breath sounds T/O, nil added			x		1
thest Xray	no hyperinflation			X		
Other						1
ilrway Clearance						1
Oral/Nasal Suction Requirement	None					+
rache Suction Requirement	frequent, sticky = normal for pt		x	×		managed by current ne
thest Physiotherapy Requirement	none			×		and suctioning.
stable, unstable, variable)	none -			^		<u> </u>
Other						
re OWV function						1
Ipper airway airteak (cervical uscultation)	some		x		Manometry and co2	1
itoma airleak	none			x		1
/oice/communication	bursts of vocalisation		×		Manometry and co2	1
Cough	fair		ŷ		vincuy and coz	Normal for patient
wallow Function	present		*			reonnacioi pauent
				*		
eed regime (oral, continuous, bolus)	NG bolus		х			Mindful of assessment timing if around feeds
Other						
Medications						
aliva management	none			x		
thest secretion management	saline nebs (0.9%) 3 hourly			х		
nebulisers)						
Seizure medications	none			×		
				V		1
one medication	none					
one medication	none			,		
one medication Ither				<u> </u>		
One medication Other Progress to OWV Trial (yes/no)	Date of Trial	Trial Outcome	Evaluation Lack of space around trache tubi	Future  Await growth, weight gain a		

The authors successfully developed a standardised OWV decisionmaking tool for use within their hospital trust (figure 1) which was intuitive to navigate and effectively identified risks and challenges associated with OWV use. It facilitated structured discussions in multi-professional meetings, guiding the timing of OWV introduction and risk mitigation strategies.

### CONCLUSIONS

This OWV decision-making tool is a crucial step toward standardising clinical decisions, improving patient safety, and optimising the quality, appropriateness, and timing of OWV interventions. Its structured framework ensures a patient-centered approach, facilitating individualised risk-benefit analysis within each patient's clinical context. By highlighting key indications and cautions, it encourages multidisciplinary collaboration and informed decisions making.

Colleagues have recognised the tool's value in supporting junior SLT and RP education and fostering multi-professional skill development. Family feedback was overwhelmingly positive, with improved engagement, clearer communication and better experiences for children and their families.

The pilot study emphasised the tool's reliance on the expert clinical judgment of the experienced SLT and PT. Future adaptations, such as refining the RAG format into a formal risk assessment tool, could expand its use across a broader professional base, supporting less experienced staff.

The standardised data collection enabled by this tool supports consistent tracking of patient outcomes across diverse diagnostic populations, facilitating future audits and research. By identifying key factors influencing OWV success or failure, it informs clinical practice improvements, enhances patient experiences, and contributes to better outcomes, potentially reducing hospital stays and ventilation dependency.

### REFERENCES

With special thanks to our amazing children and families for their support with this poster

Birmingham Women's and Children's

 Brookes, I, (2019), 'Long Term Ventilation in Children', Paediatrics and Child Health, 29:4
 www.passy-muir.com • Lian, S, Teng, L, Mao, Z, Jiang, H (2022) 'Clinical Utility and future direction of the speaking valve: A review', Front Surg; 9: 13147

**NHS Foundation Trust** • Zabih, W, Holler, T, Syed, F, Russell, L, Allegro, J (2017) 'The Use of Speaking Valves in Children With Tracheostomy Tubes, Respiratory Care, December 2017, Vol 62, No 12